COMMUNIQUÉS West-GlobeNewswire

Progyny and RESOLVE to Ring the Nasdaq Stock Market Closing Bell in Recognition of National Infertility Awareness Week®
25/04/2018
New York City, April 25, 2018 (GLOBE NEWSWIRE) -- Progyny, the leading fertility benefits management company, and RESOLVE: The National Infertility Association announced today they will ring the Nasdaq Stock Market [...]
Teladoc Announces U.S. Launch of Behavioral Health Navigator
25/04/2018
First Comprehensive Suite of Telebehavioral Health Services Improves Accuracy, Care Coordination and Access, to Drive Improved Outcomes PURCHASE, NY, April 25, 2018 (GLOBE NEWSWIRE) -- Teladoc , Inc. (NYSE: TDOC ), the [...]
Cesca Therapeutics Inc. to Exhibit at Several Upcoming Cell Therapy Conferences
25/04/2018
RANCHO CORDOVA, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ: KOOL ) today announced that the Company will be exhibiting its full suite of cellular processing [...]
Sientra to Showcase OPUS™ Breast Products and miraDry fresh™ Procedure at American Society of Aesthetic Plastic Surgeons Meeting
25/04/2018
Unveils Sientra Platinum20™ Best in Class Warranty Program for OPUS Breast Implants Announces Preliminary Unaudited First Quarter 2018 Net Sales of Approximately $14.5 Million SANTA BARBARA, Calif., April 25, 2018 ( [...]
Profound Medical to Present at the 2018 Bloom Burton & Co. Healthcare Investor Conference
25/04/2018
TORONTO, April 25, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V: PRN ) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time [...]
Ascendis Pharma A/S Announces Upcoming Investor Presentations
25/04/2018
COPENHAGEN, Denmark, April 25, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND ), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet [...]
Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
25/04/2018
Patients with a 75% or greater response experienced an eight-fold increase in migraine-free days and more meaningful improvements in bodily pain and physical function BOTHELL, Wash., April 25, 2018 (GLOBE NEWSWIRE) -- [...]
Targovax ASA: Issuance of restricted stock units (RSUs) to the board members
25/04/2018
Reference is made to the annual general meeting of Targovax ASA (the "Company") on 11 April 2018 (the "AGM") where election of members to the board of directors was according to the nomination committee's proposal. At [...]
GTX Corp Sponsor and Presenter at the Safe America World Safe Symposium
25/04/2018
Patrick Bertagna GTX Corp CEO nominated to join the Safe America Board LOS ANGELES, April 25, 2018 (GLOBE NEWSWIRE) -- GTX Corp (OTCBB: GTXO ) , an Internet of Things (IoT) solutions provider in the personal location, [...]
Extendicare Announces Closing of Underwriters' $16.5 Million Over-Allotment Option of 5.00% Convertible Debentures
25/04/2018
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES MARKHAM, Ontario, April 25, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE ) announced today that it [...]
Asklepios BioPharmaceutical, Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic
25/04/2018
Pfizer, Inc. Dosed First Patient in its Mini-Dystrophin Gene Therapy Phase 1b Trial Another AskBio Platform Product to be Acquired by Big Pharma Novartis CHAPEL HILL, N.C., April 25, 2018 (GLOBE NEWSWIRE) -- Asklepios [...]
Achaogen to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 4, 2018
25/04/2018
SOUTH SAN FRANCISCO, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO ), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram- [...]
AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
25/04/2018
CHICAGO, April 25, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ: AVXS ), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, [...]
Rick Van Kirk, CEO of Pro-Dex, Inc. Returns to “Stock Day” with Everett Jolly
25/04/2018
PHOENIX, April 25, 2018 (GLOBE NEWSWIRE) -- Pro-Dex, Inc. (NASDAQ: PDEX ) (“Pro-Dex” the “Company”), CEO Rick Van Kirk joined Everett Jolly on “Stock Day” Podcast. “The Company is close to releasing its first Pro-Dex [...]
Cue Biopharma Announces Appointment of Anish Suri, Ph.D. as Chief Scientific Officer
25/04/2018
Dr. Suri’s appointment to senior leadership team adds depth and expertise in immunology and translational studies CAMBRIDGE, Mass., April 25, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc. (NASDAQ: CUE ), an innovative [...]
Insmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018
25/04/2018
BRIDGEWATER, N.J., April 25, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will [...]
Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
25/04/2018
Efficacy and Safety Data in Patients on ZX008 Who Previously Failed Stiripentol Treatment Prior to Entry into First Phase 3 Trial (Study 1) Comparable to Results from Full Study 1 Population Patients on ZX008 Also [...]
Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform
25/04/2018
The intravaginal ring technology platform is designed to deliver targeted and sustained pharmaceutical formulations addressing unmet needs in women’s health SAN DIEGO, April 25, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience [...]
Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018
25/04/2018
PHILADELPHIA and OXFORD, U.K., April 25, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, will announce financial results for the First Quarter 2018 and [...]

Pages